CIK 0001628171 · Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472029180
- Phone
- 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-21 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −80,000 | 344,085 | ||
| 2026-06-29 | Patel Sushil Director | Option exercise 10b5-1 | +2,955 | $37.54 | $111K | 27,236 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −300 | $183.17 | $55K | 26,936 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −900 | $184.59 | $166K | 26,036 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −1,100 | $185.90 | $204K | 24,936 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −858 | $186.92 | $160K | 24,078 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −300 | $187.83 | $56K | 23,778 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −100 | $188.57 | $19K | 23,678 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −600 | $190.55 | $114K | 23,078 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −541 | $191.87 | $104K | 22,537 |
| 2026-06-29 | Patel Sushil Director | Sale 10b5-1 | −881 | $192.61 | $170K | 21,656 |
| 2026-06-29 | Patel Sushil Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,955 | 13,000 | ||
| 2026-06-24 | Anders Jack Chief Financial Officer | Option exercise 10b5-1 | +20,000 | $18.56 | $371K | 143,269 |
| 2026-06-24 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −4,553 | $167.35 | $762K | 138,716 |
| 2026-06-24 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −9,496 | $168.20 | $1.6M | 129,220 |
| 2026-06-24 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −5,651 | $169.24 | $956K | 123,569 |
| 2026-06-24 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −300 | $170.32 | $51K | 123,269 |
| 2026-06-24 | Anders Jack Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | +20,000 | 20,600 | ||
| 2026-06-18 | Kim Lorence H. Director | Grant or award | +1,191 | 74,281 | ||
| 2026-06-18 | Kim Lorence H. Director | Grant or award · Stock Option (Right to Buy) | +3,127 | 3,127 |
Page 7 of 18 · 352 trades